MedTrace Logo

Intense Pulsed Light in Meibomian Gland Dysfunctions

NCT04147962 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 45

Last updated 2022-05-13

No results posted yet for this study

Summary

Dry eye disease (DED) is an extremely common disease whose meibomian gland dysfunction is the main etiology.

Polychromatic intense pulsed light (IPL) is a promising new therapeutic alternative but few clinical data have been published.

A new IPL device has recently been marketed: LACRYSTIM (QUANTEL, France). The investigators have been using it in our clinical practice since June 2019.

The investigators present a retrospective study on our first clinical results.

Conditions

  • Dry Eye Syndromes
  • Meibomian Gland Dysfunction

Interventions

DEVICE

intense pulsed light (usual practice)

collection data : parameters used for each treatment session: duration of treatment session and intensity of intense pulsed light

Sponsors & Collaborators

  • Quantel Medical

    collaborator INDUSTRY

  • Centre Hospitalier Universitaire de Saint Etienne

    lead OTHER

Principal Investigators

  • Marie Caroline TRONE, MD · CHU de Saint Etienne

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-10-25
Primary Completion
2020-06-01
Completion
2020-06-01

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04147962 on ClinicalTrials.gov